Heron Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heron Therapeutics, Inc. (HRTX) on April 28, 2025. The report discloses the appointment of a new Chief Operating Officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Mark Hensley as Chief Operating Officer, effective April 28, 2025. Mr. Hensley brings prior experience as CEO of Veloxis Pharmaceuticals and holds leadership roles at Cornerstone Therapeutics and Chiesi USA.
Compensation and Equity Arrangements
The Compensation Committee approved the following arrangements for Mr. Hensley:
- Base Salary: $553,000 annually.
- Cash Bonus: Target of $276,500 (50% of base salary), pro-rated for 2025.
- Inducement Stock Option: 500,000 shares with a 10-year term; 25% vests on the first anniversary, with the remainder vesting monthly over three years.
- Inducement RSUs: 500,000 restricted stock units vesting 25% annually over four years.
- Inducement Performance Stock Option (PSO): Up to 900,000 shares contingent on achieving specific stock price goals.
These awards were granted outside the Company's 2007 Equity Incentive Plan but pursuant to its terms, approved under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. Mr. Hensley also entered into a Management Retention Agreement.
Investor Verification Checklist
- Verify the current stock price to determine the exercise price for the 1.4 million total inducement options/RSUs.
- Review the specific stock price goals required for the 900,000 Performance Stock Options.
- Confirm the pro-rated bonus calculation for the remainder of the 2025 fiscal year.
- Check the Company's definitive proxy statement (Schedule 14A) filed April 29, 2025, for details on the Management Retention Agreement terms.